Trial Profile
MPDL3280A Treatment in Patients With Locally Advanced or Metastatic Solid Tumors After or During Investigational Imaging
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Non-small cell lung cancer; Solid tumours
- Focus Therapeutic Use
- 01 Feb 2024 Status changed from active, no longer recruiting to completed.
- 02 Jan 2024 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 14 Feb 2023 Status changed from recruiting to active, no longer recruiting.